November 2017 Volume 13, Issue 11
Volume 13, Issue 11 | November 2017
November 2017
In this Issue
Business & Government Policy
Making a PACT with NIH
Five-year public-private R&D program established as part of Cancer MoonshotNew cancer answer
NanOlogy platform takes chemo directly to the tumorOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsPatent Docs: Allergan avoids PTAB review by assigning patents to Mohawk Nation
While a creative solution to avoid patent challenges, this is a move that will likely gain at least some attention from Congress to possibly curb similar actions in the futureResearch & Development
‘Broader’ support for tech advancement
New commitment received at Broad will establish Merkin Institute for Transformative Technologies in HealthcareMaking a successful HIV vaccine
Sugar molecules on HIV envelope are likely target, according to TSRIOSE and Inserm team up on immuno-oncology
Research to focus on targeting a new suppressive myeloid cell receptorA pair of NIH awards for JAX
The Jackson Laboratory gets $12.8 million in grants to research chronic fatigue and eye diseaseClinical Trials
VARI scores twice with SU2C Catalyst
Total of 10 grant awards given out for clinical trials on various cancersJust a drop away from relief?
SciFluor announces positive results of Phase 1/2 study on eye drops for diabetic macular edemaPersonalized biologics for rare skin disease
Fibrocell technology treats patients with cells derived from their own tissueChange of direction for Prothena
Disappointing Phase 1b results cause company to halt PRX003 program in psoriasisOut of the starting gate
A roundup of clinical trial startups and initial breakthroughsEditor's Focus
Blood will tell: Hematology in review
Combing through my inbox, it seems news of therapeutics for (and research into) blood-related diseases, from hemophilia to leukemia, has picked up a little recently...so we thought we'd share some of that news with youCommentary
Out of order: Art and science
We want to believe that science is rational and predictable but more often than not, this is only true in hindsight, once we finally “understand” what we are looking at, having viewed it from multiple angles and tested it under a variety of conditions. And even then, the seemingly chaotic nature of science surprises us, and not always in a good way.A life-sciences columnist with a twist: Getting to know Randy
Though he's been with us for more than a decade, we thought we'd introduce (or, for many of you, re-introduce) one of our two regular columnistsSpecial Reports
Special Report on Sequencing: Qualifying statements
Are expanding applications pushing next-gen sequencing beyond its limits?Feature
2017 ASCB-EMBO Show Preview: Showing love for cells in Philly
For the first joint outing of ASCB and EMBO in annual meeting form, the ‘City of Brotherly Love’ will play hostContract Services
More room for growth
ADC Bio commits $11M for new clinical, commercial drug manufacturing plantCPhI report highlights unpredictability in CDMO growth
Flow chemistry, oncology, other aspects to grow, but the rate of change remains unclearContract tech roundup
Some recent news of technology at contract research organizationsDiscovery
Selective memory
New Alzheimer’s disease candidate selectively targets toxic AβOQuality is key in ribosome assembly
‘Quality control’ step, when skipped, can cause defects that can lead to cancer and other diseaseMaking the right choice
Salk researchers says decisions in DNA repair are aided by a microproteinDiagnostics
A new angle on two cancers
ANGLE and QIAGEN form collaboration aimed at liquid biopsies for breast and prostate cancerDiagnostics tag team
IDG leverages PerkinElmer’s sequencing services to provide whole-genome sequencing to neurology patientsRosetta offloads PDx for $2.875M
Sale proceeds will be used to support commercial advancement of Reveal assayAgilent expands usage for cancer diagnostic
Dako PD-L1 IHC 28-8 pharmDx approved for two new indicationsPreclinical
Could dMAb shake up infection and cancer treatment?
Inovio’s DNA-based product shows promise combating Ebola and prostate tumorsNonclinical cardio safety combo
ApconiX Alliance and PhysioStim address drug development failure rateAll about ADCs
Eisai’s antibody-drug conjugate shows target selectivity and antitumor effects‘Granting’ a heart’s desire
NIH award for CMCs is one of University of Louisville’s largest-ever federal grants for medical researchQ&A
Q&A: Rare oncology--which types qualify?
Orphan diseases are seeing increased attention in recent years due to the appeal of markets with low competition, but rare oncology types are another beast entirely
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Reliable fluid biomarkers strategies for clinical neuroscience research
Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Understanding drug impurities: types, sources, and analytical strategies
Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Discovering cutting-edge nitrosamine analysis in pharmaceuticals
New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
